ELI LILLY & COMPANY signed an agreement with Prasco Laboratories to market the authorized generic version of Evista (raloxifene hydrochloride tablets), in 60 mg strength in the U.S. Prasco will begin shipping the product immediately. The financial terms of the agreement were not disclosed.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
